Figure 6From: Pharmacological enhancement of mGlu1 metabotropic glutamate receptors causes a prolonged symptomatic benefit in a mouse model of spinocerebellar ataxia type 1Changes in the expression of mGlu1α or mGlu5 receptors following treatments with Ro0711401 or JNJ16259685. Immunohistochemical analysis of mGlu1α and mGlu5 receptors in cerebellar serial sections of symptomatic SCA1 mice 6 days following a single s.c. injection of vehicle or Ro0711401 (10 mg/kg) is shown in (A) and (B), respectively. Note the disappearance of mGlu5 receptors from Purkinje cells after treatment with Ro0711401. Immunoblot analysis of mGlu5 receptors in wild-type mice treated acutely or repeatedly with JNJ16259685 (2.5 mg/kg) is shown in (C). Control mice were treated daily i.p. with vehicle for 6 days. The group of mice indicated as “single injection of JNJ16259685” received a 6-day treatment of vehicle followed by a single administration of JNJ16259685. The third group of mice received daily injections of JNJ16259685 for 6 days. A representative immunoblot of mGlu5 receptor is shown. Densitometric values are means ± S.E.M. of 5 mice per group. *p < 0.05 vs. mice treated with vehicle (One-way ANOVA + Fisher’s LSD). F(2,12) = 13.124. Immunohistochemical analysis of mGlu5 receptors in the cerebellum of the same mice is shown in (D).Back to article page